{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:06:59Z","timestamp":1789186019245,"version":"build-2803163510"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.4103\/sjg.sjg_90_26","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:00:51Z","timestamp":1779282051000},"page":"438-446","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["STRIDE-II treatment target achievement in inflammatory bowel disease: a cross-sectional study from a tertiary IBD centre in the United Arab Emirates"],"prefix":"10.4103","volume":"32","author":[{"given":"Noorah","family":"Al Hosani","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maitha","family":"Al Hosani","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulla A.","family":"Aljanahi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed N.","family":"Quraishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Sheikh Shakhbout Medical City, Pure Health, Abu Dhabi, United Arab Emirates"},{"name":"Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom"},{"name":"College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20260911","article-title":"Evolving clinical burden of inflammatory bowel disease in the United Arab Emirates: A two-decade analysis of diagnoses and disease severity","author":"Ahmed","year":"2025","journal-title":"Frontline Gastroenterol"},{"key":"R5-20260911","first-page":"1","article-title":"Accelerating burden of paediatric IBD in UAE: Phenotypes and treatment patterns at a single center (2012-2024)","author":"Al Atrash","year":"2026","journal-title":"Frontline Gastroenterol"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000518003","article-title":"Incidence, prevalence, and clinical epidemiology of inflammatory bowel disease in the Arab World: A systematic review and meta-analysis","volume":"6","author":"Mosli","year":"2021","journal-title":"Inflamm Intest Dis"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41575-025-01047-x","article-title":"Understanding the therapeutic toolkit for inflammatory bowel disease","volume":"22","author":"Vieujean","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"109882","DOI":"10.3748\/wjg.v31.i35.109882","article-title":"Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease","volume":"31","author":"Al Awadhi","year":"2025","journal-title":"World J Gastroenterol"},{"issue":"(Suppl 2)","key":"R9-20260911","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2024-334395","article-title":"British Society of Gastroenterology guidelines on inflammatory bowel disease in adults:","volume":"74","author":"Moran","year":"2025","journal-title":"Gut"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): A multicenter, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet Lond Engl"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): A multicenter, open-label randomised controlled trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"R13-20260911","first-page":"1243","article-title":"Suboptimal disease control assessed by STRIDE-II criteria in patients with inflammatory bowel disease treated with advanced therapies: A multinational study","volume":"12","author":"D'Amico","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10620-023-08220-9","article-title":"IBD-PODCAST Spain: A close look at current daily clinical practice in IBD management","volume":"69","author":"Vega","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.dld.2024.08.040","article-title":"Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST study","volume":"57","author":"Calabrese","year":"2025","journal-title":"Dig Liver Dis"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1080\/03007995.2024.2410928","article-title":"Assessing disease control in inflammatory bowel disease: A real world cross-sectional study in the UK (PODCAST-IBD)","volume":"40","author":"de Silva","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1007\/s10620-024-08313-z","article-title":"Effect of suboptimal disease control on patient quality of life: Real-world data from the observational IBD-PODCAST Canada trial","volume":"69","author":"Siffledeen","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R18-20260911","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae190.1168","article-title":"Effectiveness of risankizumab in an Emirati Crohn's disease cohort: Real-world insights on induction, maintenance, and dose intensification outcomes","author":"Alzaabi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s10620-023-08221-8","article-title":"Taking IBD treatment in STRIDE: How objective disease assessment is essential for the successful implementation of treat-to-target strategies","volume":"69","author":"Stallmach","year":"2024","journal-title":"Dig Dis Sci"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"e00128","DOI":"10.14309\/ctg.0000000000000128","article-title":"Treatment pathways leading to biologic therapies for ulcerative colitis and Crohn's disease in the United States","volume":"11","author":"Siegel","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"otab076","DOI":"10.1093\/crocol\/otab076","article-title":"Persistence, dosing, and other treatment patterns among Crohn's disease patients initiating biologics in United States","volume":"3","author":"Teeple","year":"2021","journal-title":"Crohns Colitis 360"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ibd\/izae055","article-title":"Crohn's Disease phenotypes and associations with comorbidities, surgery risk, medications and nonmedication approaches: The MAGIC in IMAGINE study","volume":"31","author":"Bernstein","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"R24-20260911","first-page":"377","article-title":"Comparative effectiveness of biologic therapies in preventing penetrating complications in patients with Crohn's disease","volume":"22","author":"McCurdy","year":"2024","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc"},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/gutjnl-2023-329963","article-title":"Fibrosis in IBD: From pathogenesis to therapeutic targets","volume":"73","author":"Rieder","year":"2024","journal-title":"Gut"},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa2314585","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","journal-title":"N Engl J Med"},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: A phase 3, multicenter, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/apt.70295","article-title":"Network meta-analysis: Comparative efficacy of biologics and small molecules in the induction and maintenance of remission in Crohn's disease","volume":"62","author":"Shehab","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"R31-20260911","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"R32-20260911","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","article-title":"Comparative efficacy of biologics and small molecule in ulcerative colitis: A systematic review and network meta-analysis","volume":"23","author":"Shehab","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R33-20260911","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor ? real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: Results from the EVOLVE study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis"},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicenter PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R36-20260911","doi-asserted-by":"crossref","first-page":"e001218","DOI":"10.1136\/bmjgast-2023-001218","article-title":"Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial","volume":"11","author":"Jairath","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"R37-20260911","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/ecco-jcc\/jjad142","article-title":"Definitions of Histological Abnormalities in Inflammatory Bowel Disease: an ECCO Position Paper","volume":"18","author":"Feakins","year":"2024","journal-title":"J Crohns Colitis"},{"key":"R38-20260911","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/ibd\/izad159","article-title":"Disease Clearance as a New Outcome in Ulcerative Colitis: a Systematic Review and Expert Consensus","volume":"30","author":"D'Amico","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R39-20260911","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.crohns.2014.08.011","article-title":"Systematic review: histological remission in inflammatory bowel disease. Is complete remission the new treatment paradigm? An IOIBD initiative","volume":"8","author":"Bryant","year":"2014","journal-title":"J Crohns Colitis"},{"key":"R40-20260911","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/MIB.0000000000001143","article-title":"Transmural Healing Is Associated with Improved Long-term Outcomes of Patients with Crohn's Disease","volume":"23","author":"Fernandes","year":"2017","journal-title":"Inflamm Bowel Dis"}],"container-title":["Saudi Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_90_26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:10:10Z","timestamp":1789143010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/sjg.sjg_90_26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/sjg.sjg_90_26","relation":{},"ISSN":["1319-3767","1998-4049"],"issn-type":[{"value":"1319-3767","type":"print"},{"value":"1998-4049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"2026-03-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}